Program Updates 1. Further Streamlining the Tailored Review Process Since the launch of the Pharmaceuticals With Anticipated Comparable Efficacy and Safety (PACES) process in February 2025, we...
Program Updates 1. Update: Consultation on Our Methods Guide Canada's Drug Agency (CDA-AMC) had a targeted consultation on our methods guide with interested and impacted parties in the summer of 2024...
Program Updates 1. Methods Guide Update Canada’s Drug Agency (CDA-AMC) has published our first-ever guidance document on health technology assessment (HTA) methods used in the appraisal of clinical...
Program Updates 1. Consultation on Our Methods Guide Canada’s Drug Agency is launching a consultation on our first-ever Methods Guide. The development of the guide and our open consultation are both...
Program Updates 1. Updates to the Pharmacoeconomic Submission Process and Submission Requirements Making Our Economic Model Change Logs More Transparent to Our Partners Transparency is essential in...
Program Updates 1. Update to Ethics Review Component of Complex Reviews The description of the Ethics Review for Complex Reviews has been updated to further clarify the domains of ethical...
Program Updates 1. Communicating When Manufacturers Decline to File Submissions for Eligible Drugs When a sponsor declines to file a submission with Canada’s Drug Agency for a drug that is eligible...
Program Updates 1. Working Toward Target Zero: Expanding Our Rolling Review Pilot Process Canada’s Drug Agency is taking a new step to improve the timeliness of patient access to new drugs. The action...
Program Updates 1. Expanding Our Scientific Advice Services for Canada’s Life Sciences Sector Canada’s Drug Agency is launching a new 1-year learning period in our Scientific Advice program that will...
Program Updates 1. Procedures for Provisional Funding Algorithms Provisional Funding Algorithms are a tool to support the implementation of an expert committee recommendation. Following our recent...